Closely-held Clene Nanomedicine is developing catalytic drugs to treat neurodegenerative diseases, using its clean surface nanocrystal (CSN) therapeutics platform to increase cellular bioenergy.
“We’re the first nanotherapeutics company with a novel platform that produces very reactive, clean surface nanocrystals that are, in and of themselves, the therapy,” president and CEO, Rob Etherington, says in an interview with BioTuesdays.
Nanotechnology has been used for more than a decade in diagnostics and to formulate or deliver drugs, such as those for visualizing and treating cancer, but Mr. Etherington explains that Clene is using nanotechnology in a completely different manner.
“CNM-Au8 is the first nanotherapeutic agent purposely designed to treat bioenergetic failure, which is a foundational problem for the effective treatment of neurodegenerative disease,” including multiple sclerosis (MS), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS).
Normal brain function is highly dependent on electrochemical reactions, and a lack of bioenergy can result in decreased cellular metabolism and efficiency, which can lead to neurodegenerative disease.
|
|
